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The peroxisome proliferator-activated receptors (PPARs) consist of three related transcription factors that serve to regulate a
number of cellular processes that are central to cardiovascular health and disease. Numerous pharmacologic studies have assessed
the eﬀects of speciﬁc PPAR agonists in clinical trials and have provided insight into the clinical eﬀects of these genes while genetic
studies have demonstrated clinical associations between PPAR polymorphisms and abnormal cardiovascular phenotypes. With
the abundance of data available from these studies as a background, PPAR pharmacogenetics has become a promising and rapidly
advancing ﬁeld. This review focuses on summarizing the current state of understanding of PPAR genetics and pharmacogenetics
and the important implications for the individualization of therapy for patients with cardiovascular diseases.
Copyright © 2008 Sharon Cresci. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
PPAR-alpha (PPARα), PPAR-beta/delta (PPARβ/δ), and
PPAR-gamma (PPARγ) are nuclear hormone receptor tran-
scription factor proteins encoded by similarly named genes
(PPARA;PPARD;PPARG)[1,2].EachofthePPARshasmul-
tiple promoters and more than one isoform, resulting from
alternate splicing, alternative transcription start sites or both
[3–5]. The PPARs have distinct, but overlapping, tissue ex-
pression patterns and act to coordinately regulate multiple
metabolic pathways [1, 2].
PPARα is highly expressed in the heart, liver, and skele-
tal muscles [2]. In these tissues, PPARα is the central regu-
lator of genes involved in fatty acid metabolism and appears
tomediatethebalancebetweencellularfattyacidandglucose
metabolism,particularlyattimesofmetabolicorphysiologic
stress, such as myocardial ischemia, hypertrophy, heart fail-
ure, and insulin resistance [6–15]. In addition, PPARα is in-
volved in the energy substrate and ﬁber-type switches that
occur in skeletal muscle as a result of conditioning [16]a n d
is involved in the inﬂammatory response during vascular
atherosclerosis [17–19].
PPARγ is highly expressed in both white and brown
adipocytes [2, 20, 21]. PPARγ controls adipocyte lipid stor-
ageandreleaseandisanimportantmediatorofinsulinsensi-
tivity[22,23].Inaddition,PPARγ regulatesadipocyterelease
of adipokines including tumor necrosis factor alpha (TNFα),
angiotensinogen (AGT), interleukin-6 (IL-6), and plasmino-
gen activator inhibitor type 1 (PAI-1) [24].
PPARβ/δ, also known as nuclear hormone receptor 1
(NUC 1) or fatty acid-activated receptor (FAAR), is ubiqui-
tously expressed but is expressed at higher levels in the brain,
adipose tissue, and skin [2, 25]. PPARβ/δ is thought to be
critically important in adipocyte and skeletal muscle fatty
acid oxidation and is another important mediator of insulin
sensitivity [26–28]. PPARβ/δ appears to also be involved in
obesity [26–28] and in preventing myocardial hypertrophy
via NF-κB inhibition [29–31].
T h eP P A R sa r ea b l et ob i n dm a n yd i ﬀerent ligands in-
cluding metabolic intermediates (fatty acids), pharmaco-
logic agents (ﬁbrates, thiazolidinediones), and natural herbs
(green tea) [32–36]. In the presence of ligand, PPARs bind
to their cognate regulatory elements as a heterodimer with
retinoid X receptor α [37]. Ligand binding causes a confor-
mational change that results in the recruitment of coactiva-
tors and increased transcriptional activation of target genes
[34, 35, 38, 39].
There is considerable clinical association data linking
polymorphisms of PPARA, PPARD,a n dPPARG with car-
diovasculardisease(coronaryandcarotidatherosclerosis,left2 PPAR Research
Table 1
SNP rs number
PPARA
Leu162Val rs1800206
Val227Ala rs1800234
IVS7 2498 rs4253778
IVS7 1343 rs4253776
PPARG
Pro12Ala rs1801282
25,506 C > T rs2028759
54,347 C > T rs3856806
PPARD
−87 T > C rs9658134
−4,401 C > T rs2038068
−48,444 C > T rs6902123
ventricular hypertrophy) and cardiovascular risk factors (in-
cidence of type 2 diabetes mellitus (DM), obesity, insulin
resistance, and abnormal lipid proﬁles) in populations of
diverse ethnicity. There is less data on PPAR pharmacoge-
netics, but the ﬁeld is rapidly growing and of considerable
interest to many investigators. PPAR pharmacogenetics of
ﬁbrates (gemﬁbrozil, fenoﬁbrate, and bezaﬁbrate), thiazo-
lidinediones or glitazones (troglitazone, pioglitazone, and
rosiglitazone),statins,andacarbosehaveparticularrelevance
to cardiovascular disease.
This review will discuss several signiﬁcant PPAR genetic
and pharmacogenetic associations that have been observed
withrespecttocardiovasculardisease(Table 1 providesthers
number for each SNP discussed in this review). Understand-
ing the current state of PPAR genetics and pharmacogenetics
may have important implications for the future individual-
ization of therapy for patients with cardiovascular disease.
2. PPARA
2.1. PPARALeu162Valgeneticassociations
2.1.1. Dyslipidemias
PPARA Leu162Val is a polymorphism located in the DNA
binding region of PPARα that confers diﬀerential ligand-
mediated activation of PPARα in vitro [40, 41]. Investiga-
tors from several clinical studies have observed that carri-
ers of the PPARA Val162 allele, compared to PPARA Leu162
homozygotes, have signiﬁcantly higher concentrations of
serum triglycerides, total cholesterol, LDL cholesterol, and
apolipoprotein (apo) B and apoC-III. However, there have
been exceptions, and not all studies have found an associa-
tion with all ﬁve serum lipids [41–45]. The larger trial ﬁnd-
ings, as well as the studies that have negative ﬁndings, will be
discussed here.
Recently, the association of the PPARA Leu162Val poly-
morphism with serum lipid levels was investigated in 5799
individuals from the Inter99 cohort, a Danish cohort tar-
geted for identifying parameters aﬀecting participation in
a diet and exercise intervention in the general population
[46]. In this cohort, individuals homozygous for the PPARA
Val162 allele, compared to PPARA Leu162 allele carriers,
demonstrated a 70% greater mean fasting serum triglyc-
eride level (2.2mmol/L (195mg/dL) versus 1.3mmol/L
(115mg/dL), resp.; P = .007) and a greater mean fasting
serum total cholesterol levels (6.2mmol/L (240mg/dL) ver-
sus 5.5mmol/L (213mg/dL), resp.; P = .01) [45].
These ﬁndings conﬁrmed previous observations in 2373
participants of the Framingham Oﬀspring Study. When the
association of the PPARA Leu162Val polymorphism with
variation in lipid levels was investigated in these subjects,
PPARA Val162 carriers, compared to PPARA Leu162 ho-
mozygotes, had signiﬁcantly increased serum concentrations
of total cholesterol in men (P = .0012), LDL cholesterol in
men (P = .0004), apoC-III in men (P = .009), and apoB
in men and women (P = .009 and .03, resp.) [44]. These
same investigators went on to demonstrate that the associ-
ation of the PPARA Leu 162Val polymorphism on plasma
triglycerides and apoC-III concentrations was more com-
plex and depended on the person’s regular dietary polyun-
saturated fatty acid intake. PPARA Val162 allele carriers that
had a low polyunsaturated fatty acid intake (<6% of calo-
ries) had greater serum triglyceride and apoC-III concen-
trations,compared to PPARA Leu162 homozygotes, whereas
PPARAVal162allelecarriersthathadahighpolyunsaturated
fatty acid intake had lower triglyceride and apoC-III concen-
trations, compared to PPARA Leu162 homozygotes [47].
Otherstudieshavealsoinvestigated theassociation ofthe
PPARA Leu162Val polymorphism with serum lipid response
to diets of diﬀerent fat composition. Tanaka et al. studied
59 healthy male students fed a single high-fat meal (60%
calories as fat (63% saturated fatty acids, 33% monoun-
saturated fatty acids, and 4% polyunsaturated fatty acids);
15% calories as protein; and 25% calories as carbohydrate)
following a 12-hour fast [48]. PPARA Val162 allele carri-
ers had signiﬁcantly higher fasting (baseline) total choles-
terol, LDL cholesterol, and apoB levels, compared to Leu162
homozygotes and this variation in serum lipids was main-
tained after the high-fat meal [48]. No signiﬁcant associ-
ation of the PPARA Leu162Val polymorphism with serum
triglyceride concentrations (either fasting or postprandial)
was observed (apoCIII was not measured) [48]. Paradis et al.
investigated the association of the PPARA Leu162Val poly-
morphism with serum lipid response in ten PPARA Val162
allele carriers and ten age and body mass index-matched
PPARA Leu162 homozygotes subjected to a high polyunsat-
urated fat followed by a low polyunsaturated fat diet [49]. At
baseline, the PPARA Leu162Val polymorphism was not as-
sociated with variation in serum lipids [49]. After the high
polyunsaturated fat diet, PPARA Val162 allele carriers had
a signiﬁcant decrease in plasma apoA-I levels, total choles-
terol, and LDL cholesterol (small particles), compared to the
PPARALeu162homozygotes(whodemonstratedanincrease
in plasma apoA-I levels, total cholesterol, and LDL choles-
terol (small particles): P = .02, P = .07 and P = .08, resp.)
[49].
In contrast to the aforementioned studies, when the
association of the PPARA Leu162Val polymorphism with
variations in serum lipids was investigated in 3012 healthy
middle-aged men in the second Northwick Park Health
Study (NPHS2, Northwick, UK), no association of the
PPARA Leu162Val polymorphism with serum lipids atSharon Cresci 3
baseline, or in response to therapy, wasfound [50]. Although
it was a smaller study, the Lopid Coronary Angiography Trial
(LOCAT), a clinical trial of 395 postcoronary bypass men,
with an HDL cholesterol ≤1.1mmol/L and LDL cholesterol
≤4.5mmol/L that investigated the progression of coronary
atherosclerosis in response to lipid lowering therapy with
gemﬁbrozil, [51, 52] also found no association between the
PPARA Leu162Val polymorphism and serum lipids either at
baseline, or in response to therapy [50].
2.1.2. Coronaryatherosclerosis
As discussed above, LOCAT found no association of the
PPARA Leu162Val polymorphism with variations in serum
lipids [50]. However, this study did observe that carriers of
thePPARAVal162alleleshowedsigniﬁcantlylessprogression
of atherosclerosis in both gemﬁbrozil-treated and untreated
groups [50]. No pharmacogenetic (i.e., treatment by geno-
type) interaction was found [50].
2.2. PPARALeu162Valpharmacogeneticassociations
2.2.1. Responsetogemﬁbrozil
The Helsinki Heart Study (Helsinki, Finland) was a pri-
mary prevention trial that demonstrated that randomiza-
tion to treatment with gemﬁbrozil resulted in a 34% reduc-
tion in cumulative cardiac events and a 26% reduction in
cardiac mortality [53, 54]. Subgroup analysis demonstrated
that overweight men with body mass index between 27–
40kg/m2 had the largest reduction in cardiac events in re-
sponse to gemﬁbrozil in the Helsinki Heart study [55]. Given
that the greatest response to gemﬁbrozil was observed in
this group, the association between genetic variation in the
PPARA Leu162Val polymorphism and the response to gem-
ﬁbrozil was investigated in 63 abdominally obese men in a
randomized placebo-controlled trial [56]. After 6 months of
treatment, carriers of the PPARA Val162 allele demonstrated
a 50% increase in HDL2 cholesterol compared to PPARA
Leu162 allele homozygotes who only had a 5.5% increase (P
= .03) [56]. The PPARA Leu162Val was responsible for 7% of
the variance of the change in HDL2 cholesterol and there was
a signiﬁcant genotype-by-treatment interaction between the
PPARA Leu162Val polymorphism and the increase in HDL2
cholesterol [56].
The Veterans Aﬀairs High-Density Lipoprotein Interven-
tion Trial (VA-HIT) study of patients with known ischemic
heart disease, selected for low levels of HDL cholesterol
(mean of 32mg/dL), demonstrated that randomization to
gemﬁbrozil therapy resulted in a 22% reduction in relative
risk of coronary events and a 31% reduction in cerebral vas-
cularevents[57–59].InVA-HIT,thesubgroupthatbeneﬁted
the most in reduction of cardiovascular events in response to
gemﬁbrozil were those patients that had DM or insulin re-
sistance [60, 61]. Given that this group had demonstrated
the greatest response, the association between genetic vari-
ation in the PPARA Leu162Val polymorphism and the re-
sponse to gemﬁbrozil was investigated [62]. VA-HIT patients
with DM or insulin resistance treated with gemﬁbrozil who
were PPARA Leu162 homozygotes had a greater absolute re-
ductionincardiovascularevents(12.1%reductioncompared
to treatment with placebo; P = .06) compared to carriers of
the PPARA Val162 allele who had a nonsigniﬁcant reduction
(9.9% compared to treatment with placebo; P = .28) [62].
Furthermore, in VA-HIT patients without DM or insulin re-
sistance,carriersoftheVal162allelehadasigniﬁcantincrease
in cardiovascular events in response to gemﬁbrozil (7% in-
crease compared to treatment with placebo; P = .01) [62].
2.2.2. Responsetofenoﬁbrate
The Genetics of Lipid Lowering Drugs and Diet Network
(GOLDN) study investigated the response to fenoﬁbrate
(160mg) for ≥21 days in 791 men and women enrolled in
The Family Heart Study (FHS, a multicenter, family pedi-
gree study aimed to identify genetic and environmental risk
factors of cardiovascular disease) [63]. Overall, there was a
37mg/dL reduction in fasting serum triglyceride levels af-
ter treatment with fenoﬁbrate (the average of two separate
measurements obtained prior to treatment and at the end
of treatment were used). Although only reported in abstract
form to date, variation in PPARA Leu162Val polymorphism
was signiﬁcantly associated with fasting triglyceride level re-
sponse to fenoﬁbrate treatment [64]. Individuals homozy-
gous for the PPARA Val162 allele had a 73mg/dL reduc-
tion in their fasting triglyceride response to fenoﬁbrate com-
pared to PPARA Leu162Val heterozygotes (46mg/dL reduc-
tion)andPPARA162Leuhomozygotes(53mg/dLreduction;
P < .0001) [64].
2.3. PPARAVal227Alageneticassociations
2.3.1. Dyslipidemias
PPARA Val227Ala is a polymorphism located between the
DNA binding and ligand binding domain of PPARα.T h i sr e -
gion is thought to be important in heterodimerization but in
vitro experiments conﬁrming a functional diﬀerence in alle-
l e sh a v en o ty e tb e e np e r f o r m e d[ 65]. The association of the
PPARA Val227Ala polymorphism with serum lipid levels was
investigated in a study of 401 healthy Japanese individuals
presentingtomedicalclinicforroutinehealthcare[65].After
adjustment for age and body mass index, female carriers of
the Val227 allele had signiﬁcantly lower serum total choles-
terol (P =.046)andtriglyceridelevels(P =.038)comparedto
Ala227 homozygotes [65]. Male carriers of the Val227 allele
also had lower serum total cholesterol and triglyceride levels
compared to Ala227 homozygotes, but the diﬀerences were
not signiﬁcant (P = .30 and .54, resp.) [65].
Recently, the ﬁnding of this small study was conﬁrmed in
2899 Chinese individuals from the 1998 Singapore National
Health Survey (NHS98) [66]. Women PPARA Ala227 allele
carriers had signiﬁcantly lower serum total cholesterol (P =
.047) and triglyceride levels (P = .048), compared to PPARA
Val227 homozygotes, and men had lower levels that were,
again, not signiﬁcant (P = .65 and .12, resp.) [66]. In addi-
tion to these ﬁndings, this study also found a signiﬁcant in-
teraction between the PPARA Val227Ala polymorphism and4 PPAR Research
serum HDL cholesterol levels in response to dietary polyun-
saturated fatty acid intake in women suggesting a gene-
environment interaction (P-value for interaction = .049)
[66].Speciﬁcally,theauthorsfoundthat,inwomenwhowere
PPARA Ala227 allele carriers, increasing dietary polyunsatu-
rated fatty acid intake resulted in lower serum HDL choles-
terollevels.ThisresultwasincontrasttomalePPARAAla227
allelecarriers,whohadanincreaseinserumHDLcholesterol
levels, and women who were PPARA Val227 homozygotes,
who demonstrated less lowering [66].
2.4. PPARAIVS72498G>Cgeneticassociations
2.4.1. Coronaryatherosclerosis
PPARA IVS7 2498 is a polymorphism located in intron
7o fPPARA. The functional signiﬁcance of this polymor-
phism has remained elusive but signiﬁcant clinical associa-
tions have been found with this polymorphism. In LOCAT,
PPARA IVS7 2498 (designated “PPARA i n t r o n7G / Cp o l y -
morphism” in the publication) C allele carriers had a signif-
icantly greater progression of coronary atherosclerosis com-
pared with GG homozygotes [50]. No pharmacogenetic in-
teraction was noted [50]. When the association of PPARA
IVS7 2498 polymorphism with coronary atherosclerosis was
investigated in 3,012 healthy middle-aged men in NPHS2,
PPARA IVS7 2498 CC homozygotes showed a trend toward
greater incidence of ischemic events (myocardial infarction
(MI) or coronary revascularization) (HR 1.83; 95% CI 0.96–
3.51; P = .07) compared to PPARA IVS7 2498 CG heterozy-
gotes and PPARA IVS7 2498 GG homozygotes [50].
2.4.2. Leftventricularhypertrophy
The PPARA IVS7 2498 (designated “PPARA intron 7 G/C
polymorphism” in the publication) has also been associated
with physiologic left ventricular hypertrophy in 144 young
male British army recruits undergoing a rigorous ten-week
exercise program (mixed upper and lower body strength and
endurance training) [67]. This polymorphism has also been
associated with pathologic left ventricular hypertrophy in
1148 hypertensive men and women enrolled in an echocar-
diography substudy of the third monitoring trends and de-
terminants in cardiovascular disease (MONICA) Augsburg
study[67].Inbothstudies,thePPARAIVS72498Callelewas
signiﬁcantly associated with increased LV mass index [67].
2.5. PPARAIVS72498G>Cpharmacogenetic
associations
2.5.1. Responsetofenoﬁbrate
The Diabetes Atherosclerosis Intervention Study (DAIS) was
designed to investigate if fenoﬁbrate treatment of relatively
mild dyslipidemia in 418 patients with type 2DM would
be associated with less progression of coronary atheroscle-
rosis after treatment for at least 3 years with fenoﬁbrate [68].
DAIS found that fenoﬁbrate reduced the progression of an-
giographic coronary artery disease [69], the progression of
microalbuminuria (an early marker of diabetic nephropathy,
and an independent risk factor for cardiovascular disease)
[70]; and although not powered to examine clinical events,
there were fewer in the fenoﬁbrate group compared to the
placebo group [69]. Given these ﬁndings, the association be-
tween genetic variation in the PPARA IVS7 2498 polymor-
phism (designated “PPARA intron 7 G/C polymorphism” in
the publication) and response to fenoﬁbrate in DAIS was in-
vestigated[71].DAISsubjectsweredividedintohighrespon-
ders (greater than 30% reduction, chosen because 30% was
the mean reduction in DAIS) and low responders (less than
30% reduction) in their plasma triglyceride levels and the
prevalence of PPARA IVS7 2498 genotype in the two groups
wasassessed[71].Ofthe85highresponders(55%ofpopula-
tion), there was a signiﬁcantly diﬀerent prevalence of PPARA
IVS7 2498 GG homozygotes (84.7%) when compared to the
low responders (68.6%; P < .05) [71]. In stepwise logistic re-
gressionanalysis,thebestindependentpredictorsofresponse
to fenoﬁbrate treatment were baseline triglyceride level and
PPARA IVS7 2498 genotype (PPARA IVS7 2498 GG versus C
allele carriers response to fenoﬁbrate: OR 3.1; 95% CI 1.28–
7.52; P = .012) [71].
2.5.2. Responsetoacarbose
Investigators from the STOP-NIDDM trial were interested
in whether PPARA polymorphisms would be associated with
the conversion to type 2DM in response to acarbose in pa-
tients with impaired glucose tolerance [72, 73]. They inves-
tigated this association with 11 SNPs located from exon 1
to exon 8 of PPARA and found that in the acarbose-treated
group, PPARA IVS7 2498 (designated “rs4253778” in the
publication) CC homozygotes had a 2.7-fold risk of develop-
ingtype2DM(95%CI1.14–6.79;P =.03)[74].PPARAIVS7
1343 (designated “rs4253776” in the publication), a SNP lo-
cated1,155 nucleotides upstream of PPARA IVS7 2498 and
in moderate LD with PPARA IVS7 2498 (r2 of 0.565 in this
population), also had an association with the development
of type 2DM [74]. PPARA IVS7 1343 G allele carriers had
a 1.7-fold increased risk of developing type 2DM (95% CI
1.04–2.88; P = .04) and a signiﬁcant treatment by genotype
interaction was observed [74].
3. PPARG
3.1. PPARGPro12Alageneticassociations
3.1.1. Metabolictraitsandthedevelopmentoftype2DM
The PPARG Pro12Ala polymorphism is in exon B of PPARG
w h i c hi ss p e c i ﬁ ct oP P A R γ2, the PPARγ isoform restricted
to adipose tissue [75]. In vitro experiments have demon-
strated that, compared to the PPARG Pro12 variant, the
PPARG Ala12 variant has lower binding aﬃnity for a PPAR
responsive element and decreased PPARγ-activation of a re-
porter construct in response to ligand [75]. The PPARG
Pro12Ala polymorphism has been the most investigated
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The association of the PPARG Pro12Ala polymorphism
with metabolic traits and the risk/development of DM has
been investigated in individuals of all ages and of diﬀer-
ent ethnicities including Chinese and Japanese individu-
als in the Hypertension and Insulin Resistance (SAPPHIRe)
study, [76], Iranian individuals [77], obese Italian chil-
dren, [78] middle-aged and elderly Finns, [75]a n dS p a n -
ish women [79]. Although most of these studies (includ-
ing the ones mentioned here) report that PPARG Ala12 al-
lele carriers have increased insulin sensitivity compared to
PPARG Pro12 homozygotes, a recent meta-analysis of 57
studies reported that this association only held for certain
subgroups [80]. When PPARG Ala12 allele carriers were
compared to PPARG Pro12 homozygotes, only the obese
subgroup demonstrated increased insulin sensitivity [80].
However, when PPARG Ala12 homozygotes were compared
to PPARG Pro12 homozygotes (full genotype information
that allowed this analysis was only available in 12 of the 57
studies), the association of the PPARG Ala12 allele with in-
creased insulin sensitivity was more evident in all groups
[80].
More recently, the association of the PPARG Pro12Ala
polymorphism with metabolic traits and the risk of de-
veloping hyperglycemia over 6 years was investigated in
3,914 French Caucasians in the Data From an Epidemi-
ological Study on the Insulin Resistance Syndrome (DE-
SIR) cohort (of note, this study was not included in the
meta-analysis as it was published after the meta-analysis
was submitted) [81]. At baseline, PPARG Ala12 allele car-
riers had signiﬁcantly lower fasting insulin and insulin re-
sistance as determined by homeostasis model assessment
of insulin resistance (P = .001, compared to PPARG Pro12
homozygotes) [81] .A f t e r6y e a r so ff o l l o wu p ,PPARG
Ala12 allele carriers had signiﬁcantly less increase in fast-
ing insulin (P = .007, compared to PPARG Pro12 homozy-
gotes) and insulin resistance (P = .018, compared to PPARG
Pro12 homozygotes) [81]. In addition, after 6 years of fol-
low up, PPARG Ala12 allele carriers who were normo-
glycemic at baseline (n = 3,498) had signiﬁcantly less hyper-
glycemia, compared to compared to PPARG Pro12 homozy-
gotes [81].
Thisdata,aswellasveryrecentdatafrom3,548individu-
alsinthediabetespreventionprogram(DPP)[82]conﬁrmed
two earlier meta-analyses (of the literature available at time
of each meta-analysis publication) [83, 84]. This large study
reported that PPARG Pro12 homozygotes had a 1.2-fold in-
creased risk of developing type 2DM (95% CI 0.99–1.57; P
= .07) compared to PPARG Ala12 allele carriers [85]. This
relative risk matched the 1.2-fold risk found in both meta-
analyses (P = .002 in the meta-analysis performed by Alt-
shuler et al.) [83, 84].
3.1.2. Coronaryandcarotidatherosclerosis
Several studies have investigated the association of the
PPARG Pro12Ala polymorphism with coronary artery dis-
ease and/or myocardial ischemic events, however, some have
yieldedcontradictoryresults[86–88].14,916menenrolledin
the Physicians’ Health Study [89] were followed for a mean
of 13.2 years and the association between PPARG Pro12Ala
polymorphism and MI was assessed [88]. PPARG Pro12Ala
genotype was compared in 523 individuals who developed
an MI, and 2,092 who did not show evidence of an MI [88].
Of those individuals who developed an MI, the frequency of
PPARG Ala12 allele carriers was signiﬁcantly less than in the
controls, with a decreased risk of subsequent MI (hazard ra-
tio HR = 0.77; 95% CI 0.60–0.98; P = .034) [88]. This re-
lationship held even after controlling for traditional cardiac
risk factors.
In contrast, a study of 2,016 patients with type 2DM
from the genetic portion of the continually updated dataset
known as the Diabetes Audit and Research in Tayside Scot-
land database (Go-DARTS) [87], a borderline, nonsigniﬁ-
cant association of the PPARG A l a 1 2a ll e l ec a rri e r swi t hn o n -
fatal MI or revascularization (HR 0.54; 95%CI 0.27–1.08; P
= 0.08, compared to PPARG Pro12 homozygotes) was ob-
served for the entire group. Subgroup analysis demonstrated
a signiﬁcant association if patients younger than 70 years old
at time of enrollment were assessed separately (HR 0.43; CI
0.18–0.99; P = .05) or if patients younger than 70 year old
at time of enrollment with no prior history of stroke, MI, or
revascularization were evaluated for time to ﬁrst event (HR
0.21; CI 0.06–0.69; P = .01) [87].
WhentheassociationofPPARGPro12Alapolymorphism
withtherisk ofcoronaryarterydiseasewasassessedprospec-
tively in women enrolled in the Nurses’ Health Study (8
y e a r sm e a nf o l l o wu p )a n di nm e n( 6y e a r sm e a nf o l l o w
up) enrolled in the Health Professionals Follow-Up Study
(HPSF) [86], carriers of the PPARG Ala12 allele again had
an increased risk of MI [86]. 249 women and 266 men with
MI were compared to nested case-controls and matched for
age, smoking status, and phlebotomy date [86]. Men car-
riers of the PPARG Ala12 allele had an increased risk of
MI or cardiac death (RR = 1.44; CI 1.00–2.07; P = .05)
[86]. There was no statistical diﬀerence in nonfatal MI or
cardiac death in women carriers of the PPARG Ala12 al-
lele (RR = 1.17; CI 0.82–1.68; P = .39) [86]. When data
were pooled for men and women, carriers of the PPARG
Ala12 allele had an increase risk of MI or cardiac death
(RR = 1.30; CI 1.00–1.67; P = .05) and, when stratiﬁed
by body weight, men and women with a body mass index
≥25kg/m2had a 1.68-fold increase in risk (CI 1.13–2.50; P =
.01) [86].
A study of 267 Korean individuals (158 males and
109 females) referred for coronary angiography for chest
pain, found no signiﬁcant association between the PPARG
Pro12Ala polymorphism and prevalence or severity of coro-
nary artery disease [90]. While the results from these stud-
ies may seem contradictory, there are obvious diﬀerences
in study design, patient cohorts, primary end-points, and
power. In addition, it is possible that geographic and ethnic
diﬀerences in allele frequencies may contribute to variability
in the study ﬁndings.
An association has also been observed between the
PPARG Pro12Ala polymorphism and carotid intima media
thickness [91, 92]. In two studies involving over 300 patients,
carriersofthePPARGAla12allelehadlesscarotidintimame-
dia thickness measured by B-mode ultrasound [91, 92].6 PPAR Research
3.2. PPARGPro12Alapharmacogeneticassociations
3.2.1. Responsetorosiglitazone
The PPARG Pro12Ala polymorphism resides in the ligand
binding domain of PPARγ and could therefore result in
diﬀerent aﬃnity to bind TZDs. Variation in the PPARG
Pro12Ala polymorphism and response to rosiglitazone was
investigated in 198 men and women with type 2DM (HbA1C
valuesbetween7.5–11.5%andfastingglucosesbetween140–
250mg/dL) treated with rosiglitazone for 12 weeks [93]. The
decreaseinfastingglucoseinresponsetothedrugwassigniﬁ-
cantlygreaterincarriersofthePPARGAla12allelecompared
to PPARG Pro12 homozygous patients [93]. Improvement in
HbA1C was also signiﬁcantly better in carriers of the PPARG
Ala12allelecomparedtoPPARGPro12homozygouspatients
[93]. In addition, 86.67% of PPARG Ala12 allele carriers re-
sponded to rosiglitazone (deﬁned by a greater than 15% de-
crease in HbA1C levels and/or a greater than 20% decrease in
fasting glucose level) compared to 43.72% of PPARG Pro12
homozygous patients (P = .002) [93].
3.2.2. Responsetoacarbose
Investigators from the STOP-NIDDM trial were interested in
whether PPAR polymorphisms would be associated with the
conversion to type 2DM in response to acarbose in patients
with impaired glucose tolerance [72, 73]. They found that
women treated with acarbose homozygous for the PPARG
Pro12allelehadincreasedriskofdevelopingtype2DMcom-
pared to PPARG Ala12 allele carriers treated with acarbose
(OR 2.89; 95% CI 1.20–6.96; P = .018) but found no signiﬁ-
cant diﬀerence in the men [72]. The authors did not provide
an explanation for the gender diﬀerences.
3.3. PPARG54,347C>Tgeneticassociations
3.3.1. Coronaryatherosclerosis
The PPARG 54,347 C > T polymorphism (also referred to as
PPARG 161 C > Ta n dPPARG 14,311 C > T) is a silent C
> T substitution (i.e., does not cause an amino acid change
in the protein) in nucleotide 161 of exon 6 [94]. No func-
tionalinformationonthispolymorphismisavailabletodate.
The PPARG 54,347 C > T polymorphism has been associ-
ated with the extent of coronary artery disease by angiogra-
phy [95], carotid intima media thickness [92], and incidence
of MI among individuals younger than age 50 [96].
3.4. PPARG54,347C>Tpharmacogenetic
associations
3.4.1. Responsetoﬂuvastatin
TheLipoproteinandCoronaryAtherosclerosisStudy(LCAS)
was a randomized, placebo-controlled study of 429 sub-
jects, 35–70 years old, with at least one 30–75% diameter
stenosis on coronary angiography and LDL cholesterol of
115–190mg/dL designed to assess the regression in coro-
nary atherosclerosis (as measured by within-patient per-
lesion change in minimal lumen diameter by quantitative
coronary angiography) in response to ﬂuvastatin [97, 98].
After 2.5 years of treatment with ﬂuvastatin, mean LDL
cholesterolwasreducedby23.9%,andchangeinminimallu-
men diameter by quantitative coronary angiography was sig-
niﬁcantly less in the ﬂuvastatin-treated group (0.028 mm de-
crease in diameter in the ﬂuvastatin-treated group compared
to 0.100 mm decrease in diameter in the placebo group; P <
.01) [99]. Clinical event rates had a trend towards beneﬁt in
the ﬂuvastatin-treated group but were not statistically signif-
icant [99].
Genetic variation of PPARG 54,347 C > T( d e s i g n a t e d
“PPARG 161 C > T” in the publication), PPARG Pro12Ala,
and PPARG 25,506 C > T as well as the association with
baseline lipid parameters and response to ﬂuvastatin was as-
sessed in 372 individuals from LCAS [100]. PPARG haplo-
typewasassociatedwiththedegreeofcoronaryatherosclero-
sis (mean number of coronary lesions; P = .026) and changes
in minimum lumen diameter (P = .022) in response to ﬂu-
vastatin[100].PPARAand PPARDpolymorphisms were also
assessed: no associations were found with PPARA genotype
or haplotype; PPARD associations are discussed below [100].
3.5. PPARGhaplotypepharmacogeneticassociations
3.5.1. Responsetotroglitazone
The Troglitazone in the Prevention of Diabetes (TRIPOD)
study was a placebo-controlled trial designed to test if TZD
therapy could prevent the development of type 2DM in His-
panic women with previous gestational DM [101, 102]. In
this trial, the incidence of type 2DM was decreased by 55%
in the troglitazone-treated group (coincident with improve-
mentininsulinsensitivity)comparedtoplacebo[102].Inter-
estingly, 8 months after discontinuation of treatment, there
remained a statistically signiﬁcant diﬀerence in the develop-
ment of type 2DM between those treated with troglitazone
and placebo (2.3% versus 15%; P = .03) [102].
In TRIPOD, 30% of women were classiﬁed as nonre-
sponders as they were in the lowest tertile of 3 month im-
provement in insulin sensitivity and did not gain any pro-
tection from development of type 2DM [102]. Although
there was no association of the common, functional PPARG
Pro12Alapolymorphismwithresponsetotroglitazone[103],
there was an individual association of eight other PPARG
polymorphisms with troglitazone response [104]. In addi-
tion, three hapolotypes blocks were deﬁned that were in-
dependently, or jointly, involved in mediating the response
to troglitazone [104]. Speciﬁcally, individuals with the most
common haplotype within a haplotype block starting in in-
tron 1, containing the A2 promoter and ending within in-
tron 2 (designated “Block 1” in the publication) had an odds
ratio of 2.22 for nonresponse to troglitazone (P = .032),
and the most common haplotype within a haplotype, lo-
cated completely within intron 2 (designated “Block 2” in
the publication), had an odds ratio of 4.18 for nonresponse
(P = .012) [104]. In addition, the most common haplotype
within a haplotype located in the 3  untranslated region ofSharon Cresci 7
PPARG (designated “Block 5” in the publication) had a bor-
derline signiﬁcant odds ratio of 0.51 for response (P = .049)
[104].
4. PPARD
4.1. PPARD −87T>Cgeneticassociations
4.1.1. Dyslipidemias
The PPARD −87 T > C (designated “PPARD 294 T > C”
polymorphism in the publication) was one of four polymor-
phisms identiﬁed by direct sequencing of the 5  untranslated
region of PPARD in 20 unrelated healthy subjects [105]. This
polymorphismislocated87basepairsupstreamofthetrans-
lationstartsiteand294basepairsdownstreamfromthetran-
scription start site. In vitro experiments have demonstrated
functional diﬀerences of the two variants and have impli-
cated the transcriptional corepressor SP1 in contributing to
the diﬀerences [106].
When the association of the PPARD −87 T > Cp o l ym o r -
phism with variation in plasma lipid levels was investigated
in 543 healthy men (and validated in an independent cohort
of 282 healthy men), PPARD −87 CC homozygotes had in-
creasedplasmaLDLcholesterolcomparedtoPPARD −87TT
homozygotes [106].
4.1.2. Coronaryatherosclerosisandcardiacevents
Skogsberg et al. investigated whether the PPARD −87 T >
C polymorphism (designated “PPARD 294 T > C” poly-
morphism in the publication) was associated with increased
plasma-LDL cholesterol levels and/or increased risk of hav-
ing cardiac events. In the West Of Scotland Coronary Pre-
vention Study (WOSCOPS), a randomized, double-blind,
placebo-controlled trial with the primary goal of investigat-
ing the eﬀect of pravastatin in preventing cardiac events in
patients with mild-to-moderate hypercholesterolemia (LDL
cholesterol between 4.5 and 6.0mmol/L) [107]. Although
carriers of the PPARD −87 C allele had a signiﬁcantly lower
HDL cholesterol compared with the PPARD −87 TT ho-
mozygotes, there was no association of this polymorphism
with cardiac events and no genotype-by-treatment interac-
tion [107].
4.2. PPARDhaplotypepharmacogeneticassociations
4.2.1. Responsetoﬂuvastatin
Genetic variation of PPARD −87 T > C (designated “PPARD
294 T > C” in the publication) and PPARD −4401 C > T
as well as the association with baseline lipid parameters and
response to ﬂuvastatin was assessed in 372 individuals from
LCAS [100]. PPARD haplotype was associated with the de-
gree of coronary atherosclerosis (mean number of coronary
lesions) and changesin triglyceride (P = .01)and apoC-III (P
= .047) levels in response to ﬂuvastatin [100].
4.2.2. Responsetoacarbose
Genetic variation in six SNPs in PPARD in patients with im-
paired glucose tolerance and association with the conversion
to type 2DM in response to acarbose was investigated in the
STOP-NIDDM trial [72, 73]. Women treated with acarbose
carrying the C allele of PPARD −48,444 C > T( d e s i g n a t e d
“rs6902123” in the publication) had increased risk of de-
veloping type 2DM compared to TT homozygous women
treated with acarbose (OR 2.70; 95% CI 1.44–5.30; adjusted
P = .002) [73].
5. CONCLUSIONS
With their pleiotropic eﬀects on lipid metabolism, glucose
homeostasis, myocardial energetics, and responses to is-
chemia, as well as the considerable evidence linking genetic
polymorphisms identiﬁed within the PPAR complex to com-
mon cardiovascular diseases, the PPAR family of transcrip-
tion factors is central to the regulation of a number of key
cellular pathways that impact on normal and pathologic car-
diovascular physiology and thus represent very promising
targets for further advances in pharmacologic intervention.
Early pharmacogenetic investigations into the associations of
a select few of these polymorphisms with patient responses
to drug therapy have yielded important clues to commonly
observed variability in both response and outcomes. Given
the central role of the PPARs in critical metabolic pathways,
this experience points the way to a future where knowledge
of relevant PPAR genotype might be utilized to guide more
appropriately tailored and individualized therapy.
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